Bluesight for Controlled Substances announces rebrand to ControlCheck™
Bluesight for Controlled Substances announces rebrand to ControlCheck™
It’s with great pleasure that we announce Bluesight for Controlled Substances’ rebrand to ControlCheck. This…
Congressional Legislation Seeks to Ensure “Equitable Treatment” in the 340B Program
Authored by Alan J. Arville, J.D. and Kala K. Shankle, J.D.of Epstein Becker Green In…
Staff Should Know to Report Suspected Diversion
Ensure education for recognizing/reporting suspicious behaviors Reprinted with permission from New Perspectives, Journal of the…
Top 3 Areas Where CostCheck™ Customers Are Seeing the Most Savings.
Top 3 Areas Where CostCheck™ Customers Are Seeing the Most Savings. By Hannah Kanfer BluesightⓇ …
What Does ASHP’s Revised Drug Diversion Guidelines Mean for Your Hospital?
What Does ASHP’s Revised Drug Diversion Guidelines Mean for Your Hospital? By: Sandy Still, PharmD…
Drug Shortages, Variance Spikes and Other Key Takeaways from the Diversion Quarterly.
By Hannah Kanfer BluesightⓇ released the Q2 2022 Diversion Quarterly, sharing data from its…
Why a Next-Generation Drug Diversion Solution is Vital for Hospitals.
By: Doug Zurawski, Pharm.D. Drug diversion is any act or deviation that removes a…
The Pandemic’s Continued Strain On Labor And Other Key Takeaways From The Diversion Trends Report
Kit Check recently released its 2022 Diversion Trends Report. In the report, Kit Check analyzed…
KitCheck™ Releases New Medication Pricing Information Function as First Step Towards Further Product Integration.
By Hannah Kanfer KitCheck recently released a new feature that integrates medication pricing information into…
BluesightⓇ Partners with Fagron to Expand the Availability of Pre-Tagged Medication
By Hannah Kanfer Recently, Bluesight announced its partnership with Fagron in launching RFID tagged, ready-to…